Skip to main content
. 2021 Jun 16;6(9):1–9. doi: 10.1001/jamacardio.2021.1810

Figure 2. Median Low-Density Lipoprotein Cholesterol (LDL-C) Over 2 Years of Follow-up in the GOULD Registry.

Figure 2.

GOULD indicates Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. To convert LDL-C levels convert to millimoles per liter, multiply by 0.0259.